Beyond Air, Inc. (XAIR) stock
XAIRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/3084% below fair value
$1.85−0.16 (-7.96%)
Close on Nov 18, 2026Market cap $1.77MP/E –Yield –
Beyond Air r&d expenses
Research and development expenses are spending on new products and technology.
Beyond Air's R&D Expenses for the twelve months ending Jun 30, 2026 was $9.11M, down 34.6% year over year. For fiscal 2026 it was $10.24M, down 39.2% from the year before. The highest annual figure on record is $24.36M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $10.24M | -39.2% |
| FY2025 | Mar 31, 2025 | $16.86M | -30.8% |
| FY2024 | Mar 31, 2024 | $24.36M | +44.9% |
| FY2023 | Mar 31, 2023 | $16.81M | +42.4% |
| FY2022 | Mar 31, 2022 | $11.80M | -6.5% |
| FY2021 | Mar 31, 2021 | $12.62M | +18.5% |
| FY2020 | Mar 31, 2020 | $10.65M | +139.9% |
| FY2017 | Dec 31, 2017 | $4.44M | – |
| FY2016 | Dec 31, 2016 | -$673.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $1.96M | -36.5% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $2.28M | -30.1% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $2.43M | -19.2% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $2.45M | -46.6% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $3.09M | -48.6% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $3.26M | -42.8% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $3.01M | -56.1% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $4.59M | -35.7% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $6.01M | +28.0% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $5.70M | +38.0% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $6.84M | +36.8% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $7.13M | +60.2% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $4.70M | +45.5% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $4.13M | +11.3% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $5.00M | +96.6% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | $4.45M | +58.6% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $3.23M | +17.7% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $3.71M | +101.1% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $2.54M | -22.8% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $2.81M | -10.8% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $2.74M | -36.7% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $1.85M | -36.3% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $3.29M | +27.6% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $3.15M | +10.4% |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $4.33M | +86.4% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $2.89M | +138.9% |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | $2.58M | +116.3% |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | $2.85M | +382.2% |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $2.32M | +61.5% |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | $1.21M | +1111.6% |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | $1.19M | +1429.5% |
| Q2 FY2017CQ2 2017 | Jun 30, 2017 | $591.00K | +118.1% |
| Q1 FY2017CQ1 2017 | Mar 31, 2017 | $1.44M | +542.3% |
| Q4 FY2016CQ4 2016 | Dec 31, 2016 | $100.00K | – |
| Q3 FY2016CQ3 2016 | Sep 30, 2016 | $78.00K | – |
| Q2 FY2016CQ2 2016 | Jun 30, 2016 | $271.00K | – |
| Q1 FY2016CQ1 2016 | Mar 31, 2016 | $224.00K | – |
See a number that looks wrong?